Livzon Pharmaceutical Partners on Influenza Vaccine Development

Livzon Pharmaceutical Group (HK:1513) has released an update.

Livzon Pharmaceutical Group has entered into a Patent and Technology Transfer Agreement with South China Vaccine Co. for the development of an influenza recombinant protein vaccine. The agreement involves transferring project rights and technology to Livzon MAB, a subsidiary of Livzon Pharmaceutical, in exchange for fees and royalties. This move positions Livzon MAB to advance in the clinical trials approved by the National Medical Products Administration.

For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.